Clinical trials
Tuberculosis, Pulmonary trials in South Korea
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
17 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 8 |
| Unknown status | 5 |
| Recruiting | 2 |
| Not yet recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Seoul National University Hospital | 6 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 |
| Jae-Joon Yim | 1 |
| LigaChem Biosciences, Inc. | 1 |
| National Cancer Center, Korea | 1 |
| Pusan National University Hospital | 1 |
| Quratis Inc. | 1 |
| Samsung Medical Center | 1 |
| University of Ulsan | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Tuberculosis, Pulmonary | 17 |
| Tuberculosis | 6 |
| Tuberculosis, Multidrug-Resistant | 3 |
| Extensively Drug-Resistant Tuberculosis | 2 |
| Latent Tuberculosis | 2 |
| Lung Neoplasms | 1 |
| Pneumonia, Mycoplasma | 1 |
| Stomach Neoplasms | 1 |
Trials
Showing 76 to 17 of 17. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.